Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer

Journal of Clinical Pathology

Volumn 54, Issue 9, 2001, Pages 669-674

  Jager D ^a   Jager E ^a   Knuth, A ^a  

^a KRANKENHAUS NORDWEST   (Germany)

Author keywords

Antigen specific T cell response; Tumour antigens

Indexed keywords

CYTOKINE; DIFFERENTIATION ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PEPTIDE; PROTEIN; TUMOR ANTIGEN; VIRUS ANTIGEN;

ALLELE; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AUTOIMMUNITY; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DELAYED HYPERSENSITIVITY; DISEASE COURSE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LANGERHANS CELL; POINT MUTATION; PRIORITY JOURNAL; REVIEW; TUMOR REGRESSION;

EID: 0034852872     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.54.9.669     Document Type: Review

References (66)

1. The regressing thin malignant melanoma: A distinctive lesion with metastatic potential
2. Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection
3. Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens
4. T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin-2-dependent T-cell cultures
5. T cell responses to human malignant tumours
6. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
7. Cellular and humoral responses against cancer: Implications for cancer vaccines
8. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma
9. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes
10. Expression of MAGE genes in primary and metastatic cutaneous melanoma
11. A non-apeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T-lymphocytes directed against tumor antigen MZ2-E
12. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening
13. Human neoplasms elicit multiple specific immune responses in the autologous host
14. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leucocyte antigen (HLA)-A2-binding peptide epitopes
15. Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes
16. The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
17. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
18. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
19. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes
20. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating lymphocytes associated with in vivo tumor regression
21. Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA-A2.1
22. Generation of cytotoxic T cell responses with synthetic melanoma associated peptides in vivo: Implications for tumor vaccines with melanoma associated antigens
23. Granulocyte macrophage colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo
24. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
25. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
26. A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma
27. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma
28. A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma
29. Oncogenic proteins as tumor antigens
30. Antibodies against p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
31. Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer
32. Influence of interleukin-12 on p53 peptide vaccination against established Meth A sarcoma
33. Induction of T-cell immunity against Ras oncoprotein by soluble protein or Ras-expressing Escherichia coli
34. Vaccination with mutant Ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding Ras mutation
35. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
36. HLA-class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release
37. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis
38. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells
39. Characterization of MHC class I restricted cytotoxic T cell responses to tax in HTLV-1 infected patients with neurologic disease
40. Tumor antigens recognized by cytolytic T cells
41. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
42. Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
43. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection
44. Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy
45. Cytolytic T cell reactivity against melanoma associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
46. Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma mediated by antigen-specific CTL
47. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
48. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells
49. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
50. Clonal expansion of Melan A-specific cytotoxic T lymphocytes (CTL) in a melanoma patient responding to continued immunization with melanoma-associated peptides
51. GM-CSF and TNFa cooperate in the generation of dendritic Langerhans cells
52. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
53. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
54. Serological analysis of Melan A (MART-1), a melanocyte-specific protein homogenously expressed in human melanomas
55. Immunophenotyping of melanomas for tyrosinase: Implications for vaccine development
56. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens
57. Humoral immune responses of cancer patients against "cancer-testis" antigen NY-ESO-1: Correlation with clinical events
58. Identification of NY-ESO-1 epitopes presented by HLA-DRB4 0101-0103 and recognized by CD4+ T lymphocytes of patients with NY-ESO-1 expressing melanoma
59. Detection of T helper responses, but not of human papillomavirus specific CTL responses, after peptide vaccination of patients with cervical carcinoma
60. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children
61. Tolerance, danger, and the extended family
62. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation
63. Hepatitis B virus small surface antigen particles are processed in a novel endosomal pathway for maior histocompatibility complex class I-restricted epitope presentation
64. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
65. Inverse relationship of melanocyte differentiation antigen expression in melanoma: Evidence for immunoselection of antigen-loss variants in vivo